Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contact us Login 
  • Users Online:2958
  • Home
  • Print this page
  • Email this page
Year : 2013  |  Volume : 1  |  Issue : 2  |  Page : 120-125

Hepatoprotective activity of Clearliv a polyherbal formulation in Wistar rats

1 Department of Pharmacology, J.S.S College of Pharmacy, Ootacamundl, Malaysia
2 Department of Pharmacology, J.S.S College of Pharmacy, Ootacamund, Malaysia
3 TIFAC-CORE, J.S.S College of Pharmacy, Ootacamund, Malaysia
4 Department of Pharmacology, J.S.S College of Pharmacy, Ootacamundl; Pharmacology Unit, Faculty of Pharmacy, AIMST University, Semeling, Bedong - 08100, Kedah, Malaysia
5 Green Milk Concepts, Herbal Division of Apex Laboratories, Chennai, Tamil Nadu, India

Correspondence Address:
E P Kumar
Department of Pharmacology, Karpagam College of Pharmacy, Coimbatore - 641 032, Tamil Nadu, India

Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2321-4848.123023

Rights and Permissions

Objective: To evaluate the hepatoprotective activity of Clearliv a polyherbal formulation in Wistar rats. Materials and Methods: The hepatoprotective potential of Clearliv was evaluated in thioacetamide-induced liver necrosis, DL-galactosamine [GalN]-induced liver injury, and carbon tetrachloride [CCl 4 ]-induced hepatitis models in Wistar rats. In all the models, Clearliv (at the dose levels of 800, and 1000 mg/kg) was administered for 3 days orally followed by single intraperitoneal administration of the hepatotoxicant on the last day after one hour of Clearliv administration. After 24 h of toxicant administration blood sample was collected by sino-orbital puncture in sodium EDTA tubes. The efficacy of Clearliv was evaluated by plasma biochemical parameters (AST, ALT, and ALP), and antioxidant enzyme (lipid peroxidation, catalase, superoxide dismutase, glutathione peroxidase, and hydroxyproline) levels. Results: In thioacetamide-induced necrosis, and GalN-induced liver injury models, Clearliv at 1000 mg/kg showed significant reduction in the elevated plasma liver markers, and elevated antioxidants levels. In CCl 4 -induced hepatitis, the Clearliv had favorable hepatoprotective effect, but the results were not significant. Conclusion: Clearliv 800, and 1000 mg/kg showed significant hepatoprotective effect against thioacetamide- and GalN-induced liver necrosis and injury, respectively.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded467    
    Comments [Add]    
    Cited by others 3    

Recommend this journal